Abstract
Myocardial infarction (MI) is the result of a low process of narrowing of the coronary vessels and an acute thrombotic event. The most rational approach to MI prevention should, therefore, be the prevention of coronary atheroma. However, although experimental data exist which indicate that antiaggregants are effective in preventing the formation of atherosclerotic lesions, and although a clinical study with a 5-year follow-up is presently being performed on the use of antiaggregants in inhibiting the angiographic progression of coronary scl erosis (1), at the present time the prevention of coronary atheroma does not seem to be clinically realistic. For this reason, research has been directed towards prevention of thromboocclusive events in the coronary vessels.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M. Verstraete, Registry of prospective clinical trials, fifth report, Thromb. Haemost., 48: 1–5 (1982).
N.L. Baezinger, M.J. Dillender, and P.W. Majerus, Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin, Biochem. Biophys. Res. Commun., 78: 294–301 (1977).
G.J. Roth, N. Stanford, and P.W. Majerus, Acetylation of prostaglandin synthase by aspirin, Proc. Natl. Acad. Sci. USA, 72: 3073–3076 (1975).
R.M. Robertson, D. Robertson, and L.J. Roberts, Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitory trials, N. Engl. J. Med., 304: 998 (1981).
S. Chierchia, R. De Caterina, F. Crea, C. Patrono, and A. Maseri, Failure of thromboxane A blockade to prevent attacks of vasospastic angina, Circulation, 66: 702–705 (1982).
M. Ali and J.W.D. McDonald, Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release reaction, J. Lab. Clin. Med., 89: 868–875 (1977).
E.D. Maguire, G.F. Pay, R.B. Wallis, and A.M. White, Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulfinpyrazone (Anturane) in man, Thromb. Res., 21: 321–327 (1981).
J.L. Gordon and J.D. Pearson, Effects of sulfinpyrazone and aspirin on prostaglandin I2 synthesis by endothelial cells, Br. J. Haematol., 64: 481–483 (1978).
M. Livio, S. Villa, and G. De Gaetano, Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulfinpyrazone administration to rats, J. Pharm. Pharmcol., 32: 718 (1980).
P. Steele, M. Weily, J. Rainwater, and R. Vogel, Platelet survival time and thromboembolism in patients with mitral valve prolapse, Circulation, 60: 43–54 (1979).
M. Cortellaro, C. Boschetti, G. Fassio, M. Basagni, and E.E. Polli, A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction, Acta Haematol., 61: 68–74 (1979).
S. Moncada and R. Korbut, Dipyridamole and other phospho-diesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin, Lancet, i: 1286–1289 (1978).
A. Maseri, Pathogenesis of the clinical events in ischemic-heart disease, in: “Secondary Prevention of Ischemic Cardiac Events: Present Status and New Perspectives,” E.E. Polli and M. Cortellaro, eds., Hans Huber, Bern (1983).
L.A. Cobb, R.S. Baum, H. Alvarez III, and W.A. Schaffer, Resuscitation from out-of-hospital ventricular fibrillation: 4 years follow-up, Circulation, 52(Suppl. III): 111–223 (1975).
M.A. De Wood, J. Spores, and R. Notske, Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction, N. Engl. J. Med., 303: 897–902 (1980).
R.L. Ridolfi and G.M. Hutchinson, The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis, Am. Heart J., 93: 468–486 (1977).
Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of sudden death after myocardial infarction, N. Engl. J. Med., 302: 250–256 (1980).
Anturan Reinfarction Italian Study, Sulfinpyrazone in post-myocardial infarction, Lancet, i: 237–242 (1982).
The FDA’s critique of the Anturane Reinfarction Trial, N. Engl. J. Med., 303: 1488–1492 (1980).
P.C. Elwood, A.L. Cochrane, and M.L. Burr, A randomized controlled trial of acetylsalicyclic acid in the secondary prevention of mortality from myocardial infarction, Br. Med. J., 1: 436 (1974).
P.C. Elwood and P.M. Sweetman, Aspirin and secondary mortality after myocardial infarction, Lancet, ii: 1313 (1979).
Coronary Drug Project Research Group, Aspirin in coronary heart disease, J. Clin. Dis., 29: 625 (1976).
K. Breddin, German-Austrian multicentre prospective study on the prevention of secondary myocardial infarction by aspirin in comparison to phenprocoumon and placebo, Thromb. Haemost., 38: 168 (1977).
Aspirin Myocardial Infarction Study Research Group, A randomized controlled trial of aspirin in persons recovered from myocardial infarction, J.A.M.A., 243: 661 (1980).
Persantine-Aspirin Re-Infarction Study Research Group, Persantine and aspirin in coronary heart disease, Circulation, 62: 449 (1980).
The E.P.S.I.M. Research Group, A controlled comparison of aspirin and oral anticoagulants in prevention of death, after myocardial infarction, N. Engl. J. Med., 307: 701–708 (1982).
M. Moser, W. Plains, and R. Goslin, ß-blockers and myocardial infarction, Arch. Intern. Med., 142: 1618 (1982).
W.B. Campbell, A.R. Johnson, K.S. Callahan, and R.M. Graham, Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propanolol treatment, Lancet, ii: 1382 (1981).
K.W. Hansen, R. Klysner, A. Geisler, J.B. Knudsen, S. Glarer, and J. Gormsen, Platelet aggregation and beta-blockers, Lancet, i: 224 (1982).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Polli, E.E., Cortellaro, M. (1985). Critical Review of Myocardial Infarction Prevention with Antiaggregants. In: Cajozzo, A., Perricone, R., Di Marco, P., Palazzolo, P. (eds) Advances in Hemostasis and Thrombosis. Ettore Majorana International Science Series, vol 20. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9424-6_18
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9424-6_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9426-0
Online ISBN: 978-1-4615-9424-6
eBook Packages: Springer Book Archive